Hyloris Pharmaceuticals SA (HYL.BR)

EUR 6.48

(-0.34%)

Long Term Debt Summary of Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA's latest annual long term debt in 2023 was 344 Thousand EUR , down -53.95% from previous year.
Hyloris Pharmaceuticals SA's latest quarterly long term debt in 2023 FY was 344 Thousand EUR , down -53.95% from previous quarter.
Hyloris Pharmaceuticals SA reported annual long term debt of 747 Thousand EUR in 2022, up 82.64% from previous year.
Hyloris Pharmaceuticals SA reported annual long term debt of 409 Thousand EUR in 2021, down -94.88% from previous year.
Hyloris Pharmaceuticals SA reported quarterly long term debt of 1.51 Million EUR for 2023 Q3, up 2.17% from previous quarter.
Hyloris Pharmaceuticals SA reported quarterly long term debt of 1.47 Million EUR for 2023 Q1, up 97.86% from previous quarter.

Annual Long Term Debt Chart of Hyloris Pharmaceuticals SA (2023 - 2016)

Historical Annual Long Term Debt of Hyloris Pharmaceuticals SA (2023 - 2016)

Year	Long Term Debt	Long Term Debt Growth
2023	344 Thousand EUR	-53.95%
2022	747 Thousand EUR	82.64%
2021	409 Thousand EUR	-94.88%
2020	7.99 Million EUR	36222.73%
2019	22 Thousand EUR	-99.76%
2018	9.3 Million EUR	37.28%
2017	6.78 Million EUR	174.42%
2016	2.47 Million EUR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2023 Q2	1.47 Million EUR	0.0%
2023 Q3	1.51 Million EUR	2.17%
2023 Q1	1.47 Million EUR	97.86%
2023 FY	344 Thousand EUR	-53.95%
2023 Q4	1.51 Million EUR	0.0%
2022 Q1	38 Thousand EUR	-90.71%
2022 Q2	38 Thousand EUR	0.0%
2022 Q3	747 Thousand EUR	1865.79%
2022 FY	747 Thousand EUR	82.64%
2022 Q4	747 Thousand EUR	0.0%
2021 Q1	8.3 Million EUR	3.88%
2021 FY	409 Thousand EUR	-94.88%
2021 Q4	409 Thousand EUR	275.23%
2021 Q3	109 Thousand EUR	31.33%
2021 Q2	83 Thousand EUR	-99.0%
2020 Q4	7.99 Million EUR	0.0%
2020 Q3	7.99 Million EUR	0.54%
2020 Q1	10.68 Million EUR	48459.09%
2020 FY	7.99 Million EUR	36222.73%
2020 Q2	7.94 Million EUR	-25.6%
2019 Q3	22 Thousand EUR	0.0%
2019 Q4	22 Thousand EUR	0.0%
2019 FY	22 Thousand EUR	-99.76%
2019 Q1	- EUR	0.0%
2018 FY	9.3 Million EUR	37.28%
2017 FY	6.78 Million EUR	174.42%
2016 FY	2.47 Million EUR	0.0%

Peer Long Term Debt Comparison of Hyloris Pharmaceuticals SA

Name	Long Term Debt	Long Term Debt Difference
Nicox S.A.	25.15 Million EUR	98.632%
European Medical Solutions	12.71 Million EUR	97.295%
FERMENTALG	14.33 Million EUR	97.601%
argenx SE	15.35 Million EUR	97.76%
BioSenic S.A.	15.57 Million EUR	97.791%
Celyad Oncology SA	902 Thousand EUR	61.863%
Onward Medical N.V.	16.3 Million EUR	97.89%
Oxurion NV	117 Thousand EUR	-194.017%
PHAXIAM Therapeutics S.A.	7.03 Million EUR	95.107%
Financière de Tubize SA	- EUR	-Infinity%
UCB SA	2.87 Billion EUR	99.988%